Carmichael Hill & Associates’s Ginkgo Bioworks DNA Stock Holding History

Carmichael Hill & Associates’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$25	Hold	3	–	–	﹤0.01%	775
2024 Q2	$41	Hold	3	–	–	﹤0.01%	775
2024 Q1	$140	Hold	3	–	–	﹤0.01%	753
2023 Q4	$203	Hold	3	–	–	﹤0.01%	775
2023 Q3	$218	Hold	3	–	–	﹤0.01%	772
2023 Q2	$224	Hold	3	–	–	﹤0.01%	770
2023 Q1	$160	Hold	3	–	–	﹤0.01%	766
2022 Q4	$203	Hold	3	–	–	﹤0.01%	765
2022 Q3	$0	Hold	3	–	–	﹤0.01%	821
2022 Q2	$0	Hold	3	–	–	﹤0.01%	820
2022 Q1	$0	Buy	+3	New	+$584	﹤0.01%	806
2021 Q4	–	Sell	-15	Closed	-$7K	–	807
2021 Q3	$7K	Buy	+15	New	+$7.3K	﹤0.01%	646

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Carmichael Hill & Associates's DNA Position: Q3 2024 in Review

Carmichael Hill & Associates held its Ginkgo Bioworks (DNA) position steady in Q3 2024 at 3 shares worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #775.

Carmichael Hill & Associates first reported a position in DNA in Q3 2021 and has held it in 12 quarters since. The position peaked at $7K in Q3 2021. 158 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

Carmichael Hill & Associates held 3 shares of Ginkgo Bioworks worth $25 as of Q3 2024.
Carmichael Hill & Associates left its Ginkgo Bioworks share count unchanged in Q3 2024.
Ginkgo Bioworks made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #775 holding.
Carmichael Hill & Associates first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 12 quarters since.
Carmichael Hill & Associates's Ginkgo Bioworks position peaked at $7K in Q3 2021.
158 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.